BR102012008322B8 - low-ozone, ozone-depleting aerosol medicinal formulations - Google Patents

low-ozone, ozone-depleting aerosol medicinal formulations

Info

Publication number
BR102012008322B8
BR102012008322B8 BR102012008322A BR102012008322A BR102012008322B8 BR 102012008322 B8 BR102012008322 B8 BR 102012008322B8 BR 102012008322 A BR102012008322 A BR 102012008322A BR 102012008322 A BR102012008322 A BR 102012008322A BR 102012008322 B8 BR102012008322 B8 BR 102012008322B8
Authority
BR
Brazil
Prior art keywords
ozone
low
depleting
medicinal formulations
aerosol medicinal
Prior art date
Application number
BR102012008322A
Other languages
Portuguese (pt)
Other versions
BR102012008322B1 (en
BR102012008322A2 (en
Inventor
Toneguzzo Fernando
César Vega Julio
Original Assignee
Laboratorio Pablo Cassara S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/052,054 external-priority patent/US20120207685A1/en
Application filed by Laboratorio Pablo Cassara S R L filed Critical Laboratorio Pablo Cassara S R L
Publication of BR102012008322A2 publication Critical patent/BR102012008322A2/en
Publication of BR102012008322B1 publication Critical patent/BR102012008322B1/en
Publication of BR102012008322B8 publication Critical patent/BR102012008322B8/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa. os inaladores farmacêuticos pressurizados de dose medida estão demonstrando ter tuna composição livre de cfc e totalmente ou parcialmente livre de hfa, permitindo assim a fabricação de aerossóis medicinais que não provoquem efeitos nocivos à camada de ozônio da atmosfera e com efeito estufa baixo ou desprezível.low-ozone, non-ozone depleting aerosol medicinal formulations. Pressurized metered dose pharmaceutical inhalers are being shown to have a cfc-free and wholly or partially hfa-free composition, thus allowing the manufacture of medical aerosols that do not cause harmful effects to the ozone layer of the atmosphere and have a low or negligible greenhouse effect.

BR102012008322A 2011-03-19 2012-03-19 low-ozone, ozone-depleting aerosol medicinal formulations BR102012008322B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/052,054 2011-03-19
US13/052,054 US20120207685A1 (en) 2011-02-10 2011-03-19 Non-ozone depleting medicinal formulations with low greenhouse effect

Publications (3)

Publication Number Publication Date
BR102012008322A2 BR102012008322A2 (en) 2015-08-04
BR102012008322B1 BR102012008322B1 (en) 2019-01-15
BR102012008322B8 true BR102012008322B8 (en) 2019-02-19

Family

ID=49552950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102012008322A BR102012008322B8 (en) 2011-03-19 2012-03-19 low-ozone, ozone-depleting aerosol medicinal formulations

Country Status (2)

Country Link
AR (1) AR085443A1 (en)
BR (1) BR102012008322B8 (en)

Also Published As

Publication number Publication date
BR102012008322B1 (en) 2019-01-15
AR085443A1 (en) 2013-10-02
BR102012008322A2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
CY1120605T1 (en) DRY POWDER PREPARATION INCLUDING A PHOSPHODIESTERATION INHIBITOR
EA201290375A1 (en) COMBINATION THERAPY COPD
CL2015000486A1 (en) Nicotine Composition
BR112014029738A2 (en) mixed rods for use in aerosol generating articles
UY30139A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
PE20160543A1 (en) DRY POWDER INHALER CONTAINING FLUTICASONE AND SALMETEROL
IN2014DN06501A (en)
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
UY34359A (en) ? MULTIPLE SCLEROSIS TREATMENT WITH COMBINATION OF LAQUINIMOD AND INTERFERÓN-BETA ?.
MX357619B (en) An inhaler comprising a tiotropium-containing-composition.
BR112015027017A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
ECSP14013275A (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CR20150007A (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAENE 3-SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
BR112014018767A8 (en) FUSED PYRROLDICARBOXAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM
WO2011076841A3 (en) Combination therapy for copd
TN2012000261A1 (en) Aerosol formulation for copd
BR112017023351A2 (en) fragile matrix multidrug compositions
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
CY1117596T1 (en) PHARMACEUTICAL AIRPORT COMPOSITIONS OF FORMOTEROL AND DIPROPIONAL VEHICLE
MX2015009891A (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
CL2012000947A1 (en) Metered dose inhalation suspension formulation comprising formoterol fumarate dihydrate and fluticasone propionate and microlin sodium in an hfa propellant; pharmaceutical composition; a product; use of 0.01 to 0.1% cromolyn sodium, useful in asthma and rhinitis.
BR102012008322B8 (en) low-ozone, ozone-depleting aerosol medicinal formulations
AR089101A1 (en) NASAL FORMULATION
MX2014001940A (en) Pharmaceutical aerosol product for administration by oral or nasal inhalation.

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)
B07A Technical examination (opinion): publication of technical examination (opinion)
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2506 DE 15/01/2019,QUANTO AO ITEM (72).